Drug name - Aubagio
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(3 years from now) | |
|
US6794410
(Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(4 years from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(7 years from now) | |
|
US8802735
(Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(8 years from now) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(11 years from now) | |
|
US9186346
(Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(11 years from now) | |
Drugs and Companies using TERIFLUNOMIDE ingredient
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 7MG | TABLET;ORAL | Prescription |
| 14MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.